Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Wilcoxon signed rank test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Wilcoxon signed rank test. Displaying page 1 of 1.
    EudraCT Number: 2005-005916-26 Sponsor Protocol Number: S241-GB-09 Start Date*: 2006-02-01
    Sponsor Name:Stiefel Laboratories Maidenhead Ltd
    Full Title: A phase I, single-blind, CPO solution human repeat insult patch test in healthy subjects.
    Medical condition: Not Applicable (Healthy Volunteer Study)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001295-37 Sponsor Protocol Number: CILOGIST Start Date*: 2018-10-10
    Sponsor Name:CUB HOPITAL ERASME
    Full Title: CILOSTAZOL AS IMATINIB SYNERGISER IN PATIENTS WITH UNRESECTABLE OR METASTATIC GIST TREATED BY GLIVEC®
    Medical condition: Gastrointestinal stromal tumors. Gastrointestinal stromal tumors (GISTs) start their development in special cells in the wall of the gastrointestinal (GI) tract, also known as the digestive tract.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004422-50 Sponsor Protocol Number: DM03RUP/IV/05 Start Date*: 2006-01-11
    Sponsor Name:J.Uriach y Compania S.A.,
    Full Title: A placebo-controlled, double-blind, cross-over study with rupatadine 10 mg in 30 mosquito-bite allergic adult subjects Rupatadiini-antihistamiini hyttyspistoallergiassa
    Medical condition: mosquito-bite allergic adults
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-004160-67 Sponsor Protocol Number: Protocol F1J-MC-SBCT (a) Start Date*: 2005-02-24
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Effect of Duloxetine on Valsalva Leak Point Pressure and Quantitative Rhabdosphincter Electromyography Measures in Women with Stress Urinary Incontinence
    Medical condition: stress urinary incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004137-21 Sponsor Protocol Number: 78591.041.21 Start Date*: 2021-10-28
    Sponsor Name:University Medical Center Utrecht
    Full Title: Effect of intranasal administration of palivizumab on experimental respiratory syncytial viral infection – a human challenge study
    Medical condition: respiratory syncytial virus infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001193-15 Sponsor Protocol Number: FASTERCC-001 Start Date*: 2016-07-06
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy (FASTERCC). A randomized, double-blind, phase II ...
    Medical condition: Mucositis (nasal, oral, pharyngeal, anal, or genital) is often experienced in relation to TKI and mTOR inhibitor treatment of metastatic renal cell carcinoma patients. The present trial will assess...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10064282 Vaginal mucositis LLT
    20.0 100000004856 10028130 Mucositis oral LLT
    20.0 100000004856 10065721 Anal mucositis LLT
    20.0 100000004867 10028127 Mucositis LLT
    20.0 100000004855 10065881 Pharyngeal mucositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002628-26 Sponsor Protocol Number: ZX008-1601 Start Date*: 2018-07-23
    Sponsor Name:Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc.
    Full Title: A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochlo...
    Medical condition: Lennox-Gastaut Syndrome in Children and Adults
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Ongoing) AT (Prematurely Ended) DK (Completed) GB (GB - no longer in EU/EEA) IT (Completed) SE (Completed) NL (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003184-62 Sponsor Protocol Number: J1369 Start Date*: 2014-04-23
    Sponsor Name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Full Title: A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer...
    Medical condition: Previously treated metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002547-29 Sponsor Protocol Number: ATB-203 Start Date*: 2019-11-21
    Sponsor Name:Atox Bio
    Full Title: Phase 2 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of Reltecimod as compared to placebo in addition to standard of care in patients with ...
    Medical condition: Acute kidney injury due to intra-abdominal infection/sepsis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10080269 Stage 2 acute kidney injury LLT
    20.1 100000004857 10080271 Stage 3 acute kidney injury LLT
    20.1 100000004862 10079983 Complicated intra-abdominal infection LLT
    20.0 100000004862 10040050 Sepsis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000382-16 Sponsor Protocol Number: 1063-Dara-H-VERUMM Start Date*: 2021-04-07
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Efficacy of daratumumab (Dara) retreatment using a histone deacetylase-inhibitor (HDACi: panobinostat) as a Dara-longevity-inducing, epigenetic agent in combination with bortezomib-dexamethasone ...
    Medical condition: Relapsed and refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003060-25 Sponsor Protocol Number: MEIN/22/NeRam-Hyp/001 Start Date*: 2023-03-07
    Sponsor Name:Menarini International Operations Luxembourg SA
    Full Title: Open-label, multicenter, multinational, interventional Clinical Trial to assess Efficacy and Safety of the extemporaneous combination of Nebivolol and Ramipril in hypertensive patients - ARTEMISIA ...
    Medical condition: Cardiovascular Disease Hypertensive patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 12:00:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA